





Robert Greene Sterne Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Fric K. Steffe Michael Q. Lee Steven R. Ludwio John M. Covert Robert C. Millonia Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Patrick E. Garrett

Jeffrey T. Helvey Eldora L. Ellison Thomas C. Fiala Donald R. Banowit Peter A. Jackman Jeffrey S. Weaver Brian I. Del Buono Mark Fox Evens Edward W. Yee Vincent L. Capuano Virgil Lee Beaston Theodore A. Wood Elizabeth I. Haanes Joseph S. Ostroff Frank R. Cottingham Daniel A. Klein Jason D. Eisenberg Michael D. Specht

August 15, 2006

Tracy L. Muller LuAnne M. DeSantis Helene C. Carlson Cynthia M. Bouchez mothy A. Doyle Gaby L. Longsworth Lori A. Gordon Laura A. Vogel Bryan S. Wade Bashir M.S. Ali Shannon A. Carroll Michelle K. Holoubek Marsha A. Rose Young Tang Christopher J. Walsh

W. Blake Coblentz* James I Pohl' John T. Haran Mark W. Rygiel Kevin W. McCabe Michael R. Malek*

Registered Patent Agents Karen R. Markowicz Matthew J. Dowd Katrina Yujian Pei Quach Bryan L. Skelton Robert A. Schwartzman Victoria S. Rutherford Simon J. Elliott Julie A. Heider Mita Mukherjee

Liliana Di Nola-Baron Jeffrey K. Mills Danielle L. Letting Steven C. Oppenheime

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie

Admitted only in Maryland * Admitted only in Virginia Practice Limited to Federal Agencies

WRITER'S DIRECT NUMBER: (202) 772-8615 **INTERNET ADDRESS:** FRANKC@SKGF.COM

Art Unit To be assigned

Attn: Mail Stop Amendment

Commissioner for Patents PO Box 1450

Re:

Alexandria, VA 22313-1450

U.S. Utility Patent Application

Appl. No. 10/529,221 (U.S. Nat'l Phase of PCT/US03/30238;

Int'l. Filing Date: September 26, 2003); § 371 Date: To be assigned

Targeted CD1d Molecules

Inventors:

ROBERT et al.

Our Ref:

.1843.0200001/EKS/FRC

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(b);
- 2. Listing of the cited documents on Forms PTO/SB/08A and PTO/SB/08B (11 sheets);
- 3. A copy of eleven (11) cited documents on Form PTO/SB/08A;
- 4. A copy of eighty-one (81) cited documents on Form PTO/SB/08B;
- 5. First Supplemental Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(b);
- 6. Listing of the cited documents on Forms PTO/SB/08A and PTO/SB/08B (2 sheets);
- 7. A copy of four (4) cited documents on Form PTO/SB/08A;
- 8. A copy of ten (10) cited documents on Form PTO/SB/08B; and
- 9. Return postcard.

Commissioner for Patents August 15, 2006 Page 2

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Frank R. Cottingham (

Attorney for Applicants Registration No. 50,437

FRC/pcd Enclosures

570207v1



In re application of:

ROBERT et al.

Appl. No.: 10/529,221 (U.S. Nat'l Phase

of PCT/US03/30238)

I.A. Filed: September 26, 2003

For: Targeted CD1d Molecules

Confirmation No.: 2116

Art Unit: To Be Assigned

Examiner: To Be Assigned

Atty. Docket: 1843.0200001/EKS/FRC

Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO/SB/08A and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents FP1-FP11 and NPL1-NPL81 are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents, documents US1-US3, cited on the attached Form PTO/SB/08A are not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document FP6, cited on Form PTO/SB/08A:

Document FP6, EP 0 352 761 B1, is in the German language. An English language abstract of document FP6 is attached as document NPL26.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

ROBERT et al. Appl. No. 10/529,221 (U.S. Nat'l Phase of PCT/US03/30238)

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Frank R. Cottingham Attorney for Applicants Registration No. 50,437

Date: AUG. 15, 2006

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

447481_1.DOC

Equivalent of Form PTO/SB/08A (07-05)
Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

1843.0200001/EKS/FRC

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Repartment of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Attorney Docket Number

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

(Use as many sheets as necessary)

2

AUG 1 5 2006

Application Number	10/529,221 (U.S. Nat'l Phase of PCT/US03/30238)
I.A. Filing Date	September 26, 2003
First Named Inventor	Bruno Robert
Art Unit	To Be Assigned
Examiner Name	To Be Assigned

Complete if Known

			U.S. PATENT DO	DCUMENTS		
Examiner Initials*	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
	No.1	Number-Kind Code ^{2 (If Known)}	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appea	
/M.D./	US1	5,194,425	03/16/1993	Sharma et al.		
/M.D./	US2	5,635,363	06/03/1997	Altman et al.		
/M.D./	US3	6,015,884	01/18/2000	Schneck et al.		
- + + + + + + + + + + + + + + + + + + +						
					/	
			†		 	

		Fo	REIGN PATENT DO	DCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			Relevant Passages or Relevant Figures Appear	T ⁶
	FP1	AU-B-39005/89	02/01/1990	Behringwerke		
/M.D./		AO-B-39003/89	02/01/1990	Aktiengesellschaft		L
/M.D./	FP2	WO 93/10220 A1	05/27/1993	Anergen, Inc.		
/M.D./				The Board of Trustees of		
/WI.D./	FP3	WO 96/26962 A1	09/06/1996	the Leland Stanford Junior University		
/B # 17 /	CD4	WO 07/25001 A 1	10/02/1007	The Johns Hopkins		
/M.D./ 	FP4	WO 97/35991 A1	10/02/1997	University, Schneck, and O'herrin		
/M.D./	FP5	WO 98/07441 A1	02/26/1998	Massachusetts Institute of Technology		

Examiner Signature /Marianne DiBrino/ Date Considered 08/17/2009
--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Equivalent of Form PTO/SB/08A (07-05) Approved for use through 07/31/2006.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	Substitute for form 1449/PTO			Complete if Known		
T		DION.		Application Number	10/529,221 (U.S. Nat'l Phase of PCT/US03/30238)	
INFORMATION DISCLOSURE				I.A. Filing Date	September 26, 2003	
STAT	STATEMENT BY APPLICANT			First Named Inventor	Bruno Robert	
	(Use as	many she	eets as necessary)	Art Unit	To Be Assigned	
				Examiner Name	To Be Assigned	
Sheet	2	of	2	Attorney Docket Number	1843.0200001/EKS/FRC	

			U.S. PATENT DOG			
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appea	
initiais	No.	Number-Kind Code ^{2 (If Known)}	MM-DD-YYYY	Applicant of Cited Document		
-						
						-
	.		OREIGN PATENT D			
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
			10/04/1005	Behringwerke	rippour	Ė
			10,01,12,20	Aktiengesellschaft		
/M.D./	FP7	WO 99/11775 A1	03/11/1999	President and Fellows of Harvard College, Walker, and Garboczi		
/M.D./	FP8	WO 99/13095 A1	03/18/1999	The Johns Hopkins University School of Medicine		
/M.D./	FP9	WO 99/21572 A1	05/06/1999	Sunol Molecular Corporation		
/M.D./	FP10	WO 99/64464 A2	12/16/1999	Savage		
/M.D./	FP11	WO 00/00156 A2	01/06/2000	Trustees of Dartmouth College		

447471_1.DOC

Examiner		Date	
Signature	/Marianne DiBrino/	Considered	08/17/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

Engish language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Redu RADEM Substitute for form 1449/PTO Complete if Known 10/529,221 (U.S. Nat'l Phase of Application Number PCT/US03/30238) INFORMATION DISCLOSURE I.A. Filing Date September 26, 2003 STATEMENT BY APPLICANT First Named Inventor Bruno Robert (Use as many sheets as necessary) To Be Assigned Art Unit To Be Assigned **Examiner Name** 1843.0200001/EKS/FRC 9 1 of Attorney Docket Number Sheet

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*					
/M.D./	NPL1	Abastado, JP., et al., "Dimerization of Soluble Major Histocompatibility Complex-Peptide Complexes Is Sufficient for Activation of T Cell Hybridoma and Induction of Unresponsiveness," J. Exp. Med. 182:439-447, The Rockefeller University Press (1995)			
000000000000000000000000000000000000000	NPL2	Abdel-Wahab, Z., et al., "Human Dendritic Cells, Pulsed with either Melanoma Tumor Cell Lysates or the gp100 Peptide ₍₂₈₀₋₂₈₈₎ , Induce Pairs of T-Cell Cultures with Similar Phenotype and Lytic Activity," Cell. Immunol. 186:63-74, Academic Press (1998)			
	NPL3	Alexander, J., et al., "Recognition of a Novel Naturally Processed, A2 Restricted, HCV-NS4 Epitope Triggers IFN-gamma Release in Absence of Detectable Cytopathicity," Hum. Immunol. 59:776-782, Elsevier Science, Inc. (1998)			
	NPL4	Alexander, M., et al., "Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope," Am. J. Obstet. Gynecol. 175:1586-1593, Mosby-Year Book, Inc. (1996)			
	NPL5	Altman, J.D., et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes," Science 274:94-96, American Association for the Advancement of Science (1996)			
	NPL6	Battegay, M., et al., "Patients with Chronic Hepatitis C Have Circulating Cytotoxic T Cells Which Recognize Hepatitis C Virus-Encoded Peptides Binding to HLA-A2.1 Molecules," J. Virol. 69:2462-2470, American Society for Microbiology (1995)			
200000000000000000000000000000000000000	NPL7	Bedzyk, W.D., et al., "Immunological and Structural Characterization of a High Affinity Anti-fluorescein Single-chain Antibody," J. Biol. Chem. 265:18615-18620, The American Society for Biochemistry and Molecular Biology, Inc. (1990)			
	NPL8	Bertoletti, A., et al., "Molecular Features of the Hepatitis B Virus Nucleocapsid T-Cell Epitope 18-27: Interaction with HLA and T-Cell Receptor," Hepatology 26:1027-1034, American Association for the Study of Liver Diseases (1997)			
V	NPL9	Bocchia, M., et al., "Specific Binding of Leukemia Oncogene Fusion Protein Peptides to HLA Class I Molecules," Blood 85:2680-2684, The American Society of Hematology (1995)			
/M.D./	NPL10	Bocchia, M., et al., "Specific Human Cellular Immunity to bcr-abl Oncogene-Derived Peptides," Blood 87:3587-3592, The American Society of Hematology (1996)			

Examiner Signature	/Marianne DiBrino/	Date Considered	08/17/2009
Signature	/IVIalialine Didino/	Considered	00/11/2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of ired to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449/PTO Complete if Known 10/529,221 (U.S. Nat'l Phase of Application Number PCT/US03/30238) INFORMATION DISCLOSURE I.A. Filing Date September 26, 2003 STATEMENT BY APPLICANT First Named Inventor Bruno Robert (Use as many sheets as necessary) Art Unit To Be Assigned To Be Assigned Examiner Name of 1843.0200001/EKS/FRC 2 9 Attorney Docket Number Sheet

			NON PATENT LITERATURE DOCUMENTS	
Examiner Initials* /M.D./		Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T²
		NPL11	Boitel, B., et al., "Strong Similarities in Antigen Fine Specificity Among DRB1*1302-Restricted Tetanus Toxin tt830-843-Specific TCRs in Spite of Highly Heterongenous CDR3," J. Immunol. 154:3245-3255, The American Association of Immunologists (1995)	
***************************************	:	NPL12	Boniface, J.J., et al., "Initiation of Signal Transduction through the T Cell Receptor Requires the Peptide Multivalent Engagement of MHC Ligands," <i>Immunity</i> 9:459-466, Cell Press (1998)	-
NP		NPL13	Brinckerhoff, L.H., et al., "Terminal Modifications Inhibit Proteolytic Degradation of an Immunogenic Mart-127-35 Peptide: Implications for Peptide Vaccines," Int. J. Cancer 83:326-334, Wiley-Liss, Inc. (1999)	
		NPL14	Brusic, V., et al., "Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network," Bioinformatics 14:121-130, Oxford University Press (1998)	
		NPL15	Burrows, G.G., et al., "Two-Domain MHC Class II Molecules Form Stable Complexes with Myelin Basic Protein 69-89 Peptide That Detect and Inhibit Rat Encephalitogenic T Cells and Treat Experimental Autoimmune Encephalomyelitis," J. Immunol. 161:5987-5996, The American Association of Immunologists (1988)	
000000000000000000000000000000000000000	NPL16		Casares, S., et al., "Antigen-specific Signaling by a Soluble, Dimeric Peptide/Major Histocompatibility Complex Class II/Fc Chimera Leading to T Helper Cell Type 2 Differentiation," J. Exp. Med 190:543-553, The Rockefeller University Press (1999)	
000000000000000000000000000000000000000		NPL17	Castelli, C., et al., "Novel HLA-Cw8-Restricted T Cell Epitopes Derived from Tyrosinase-Related Protein-2 and gp100 Melanoma Antigens," J. Immunol. 162:1739-1748, The American Association of Immunologists (1999)	
***************************************		NPL18	Celis, E., et al., "Identification of Potential CTL Epitopes of Tumor-Associated Antigen Mage-1 for Five Common HLA-A Alleles," Mol. Immunol. 31:1423-1430, Elsevier Science, Ltd. (1994)	
V		NPL19	Chaux, P., et al., "Identification of Mage-3 Epitopes Presented by HLA-DR Molecules to CD4 ⁺ T Lymphocytes," J. Exp. Med. 189:767-777, The Rockefeller University Press (1999)	
/M.D./		NPL20	Chikamatsu, K., et al., "Generation of Anti-p53 Cytotoxic T Lymphocytes from Human Peripheral Blood Using Autologous Dendritic Cells," Clin. Cancer Res. 5:1281-1288, The American Association for Cancer Research (1999)	

Examiner Signature /Marianne DiBrino/ Date Considered 08/17/2009
--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

To Be Assigned

Under the Paperwork Conction Acro no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449/PTO Complete if Known 10/529,221 (U.S. Nat'l Phase of **Application Number** PCT/US03/30238) I.A. Filing Date September 26, 2003 First Named Inventor Bruno Robert

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

				Examiner Name	To Be Assigned
Sheet	3	of	9	Attorney Docket Number	1843.0200001/EKS/FRC
					•

Art Unit

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
/M.D./	NPL21	Cochran, J.R., et al., "The Relationship of MHC-Peptide Binding and T Cell Activation Probed Using Chemically Defined MHC Class II Oligomers," <i>Immunity 12</i> :241-250, Cell Press (2000)	
300000000000000000000000000000000000000	NPL22	Cormier, JN., et al., "Heterogeneous Expression of Melanoma-Associated Antigens and HLA-A2 in Metastatic Melanoma In Vivo, Int. J. Cancer 75:517-524, Wiley-Liss, Inc. (1998)	
***************************************	NPL23	Dal Porto, J., et al., "A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations," <i>Proc. Natl. Acad. Sci. USA 90</i> :6671-6675, The National Academy of Sciences (1993)	
-	NPL24	Daniel, S., et al., "Relationship Between Peptide Selectivities of Human Transporters Associated with Antigen Processing and HLA Class I Molecules," J. Immunol. 161:617-624, The American Association of Immunologists (1998)	
/M.D./	NPL25	De Backer, O., et al., "Characterization of the GAGE Genes That Are Expressed in Various Human Cancers and in Normal Testis," Cancer Res. 59:3157-3165, The American Association for Cancer Research (1999)	
52/2007/2007/2007/2007/2007/2007/2007/20	wypyyy	Dialog File 351. Accession No. 8144344. Derwent WPI English language abstract for EP 352 761 A2, cited on Form PTO/SB/08A as document FP6	•
/M.D./	NPL27	Diepolder, H.M., et al., "Immunodominant CD4 ⁺ T-Cell Epitope within Nonstructural Protein 3 in Acute Hepatitis C Virus Infection," J. Virol. 71:6011-6019, American Society for Microbiology (1997)	
popopodes de la compansión de la compans	NPL28	Doolan, D.L., et al., "Degenerate Cytotoxic T Cell Epitopes from P. falciparum Restricted by Multiple HLA-A and HLA-B Supertype Alleles," <i>Immunity</i> 7:97-112, Cell Press (1997)	
-	NPL29	Esser, S., et al., "Vascular endothelial growth gactor induces VE-cadherin tyrosine phosphorylation in endothelia cells," J. Cell Sci. 111:1853-1865, The Company of Biologists Limited (1998)	-
/M.D./	NPL30	Fleischhauer, K., et al., "Functional Heterogeneity of HLA-A*02 Subtypes Revealed by Presentation of a MAGE-3-Encoded Peptide to Cytotoxic T Cell Clones," J. Immunol. 159:2513-2521, The American Association of Immunologists (1997)	

Examiner	/Mariana DiDvina/	Date	00/17/2000
Signature	/Mananne Dibrino/	Considered	08/17/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction ersons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449/PTO Complete if Known 10/529,221 (U.S. Nat'l Phase of Application Number PCT/US03/30238) INFORMATION DISCLOSURE I.A. Filing Date September 26, 2003 STATEMENT BY APPLICANT Bruno Robert First Named Inventor (Use as many sheets as necessary) Art Unit To Be Assigned To Be Assigned **Examiner Name** 1843.0200001/EKS/FRC 4 9 Sheet of Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No. 1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
/M.D./	NPL31	Gotch, F., et al., "Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2," Nature 32:881-882, Nature Publishing Group (1987)	
388889999999999999999999999999999999999	NPL32	Greten, T.F., et al., "Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19-specific CD8 ⁺ T Cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients," Proc. Natl. Acad. Sci. USA 95:7568-7573, The National Academy of Sciences (1998)	
200000000000000000000000000000000000000	NPL33	Hamad, A.R.A., et al., "Potent T Cell Activation with Dimeric Peptide-Major Histocompatibility Complex Class II Ligand: The Role of CD4 Coreceptor," J. Exp. Med. 188: 1633-1640, The Rockefeller University Press (1998)	
**************************************	NPL34	Harbury, P.B., et al., "A Switch Between Two-, Three-, and Four-Stranded Coiled Coils in GCN4 Leucine Zipper Mutants," Science 262:1401-1407, American Association for the Advancement of Science (1993)	
200000000000000000000000000000000000000	NPL35	Harvill, E.T., et al., "In Vivo Properties of an IgG3-IL-2 Fusion Protein," J. Immunol. 157:3165-3170, The American Association of Immunologists (1996)	
***************************************	NPL36	Heathcote, J., et al., "A Pilot Study of the CY-1899 T-Cell Vaccine in Subjects Chronically Infected with Hepatitis B Virus," Hepatology 30:531-536, The American Association of the Study of Liver Diseases (1999)	
999000000000000000000000000000000000000	NPL37	Höllsberg, P., et al., "Differential activation of proliferation and cytotoxicity in human T-cell lymphotropic virus type I Tax-specific CD8 T cells by an altered peptide ligand," Proc. Natl. Acad. Sci. USA 92:4036-4040, National Academy of Sciences (1995)	
200000000000000000000000000000000000000	NPL38	Kawashima, I., et al., "Identification of GP100-Derived, Melanoma-Specific Cytotoxic T-Lymphocyte Epitopes Restricted By HLA-A3 Supertype Molecules By Primary In Vitro Immunization With Peptide-Pulsed Dendritic Cells," Int. J. Cancer 75:518-524, Wiley-Liss, Inc. (1998)	
V	NPL39	Kawashima, I., et al., "Identification of HLA-A3-restricted Cytotoxic T Lymphocyte Epitopes from Carcinoembryonic Antigen and HER-2/neu by Primary in Vitro Immunization with Peptide-pulsed Dendritic Cells," Cancer Res. 59:431-435, The American Association for Cancer Research (1999)	
/M.D./	NPL40	Kim, J., et al., "Determinants of T Cell Reactivity to the Mycobacterium leprae GroES Homologue," J. Immunol. 159:335-343, The American Association of Immunologists (1997)	

Examiner		Date	
Signature	08/17/2009	Considered	08/17/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	r form 1449/PT	·o		Cos	mplete if Known
*******				Application Number	10/529,221 (U.S. Nat'l Phase of PCT/US03/30238)
INFORMATION DISCLOSURE				I.A. Filing Date	September 26, 2003
STATE	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	Bruno Robert
				Art Unit	To Be Assigned
			Examiner Name	To Be Assigned	
Sheet	5	of	9	Attorney Docket Number	1843.0200001/EKS/FRC

		Non Patent Literature Documents				
Examiner Cite No. 1						
/M.D./	NPL41	Kono, K., et al., "Identification of HER2/neu-Derived Peptide Epitopes Recognized by Gastric Cancer-Specific Cytotoxic T Lymphocytes," Int. J. Cancer 78:202-208, Wiley-Liss, Inc. (1998)				
000000000000000000000000000000000000000	NPL42	Kundu, S.K., et al., "Role of Preimmunization Virus Sequences in Cellular Immunity in HIV-Infected Patients during HIV Type 1 MN Recombinant gp 160 Immunization," Aids Res. Hum. Retroviruses 14:1669-1678, Mary Ann Liebert, Inc. (1998)				
оороски долоского долого д	NPL43	Lachman, L.B., et al., "Cytokine-Containing Liposomes as Adjuvants for Subunit Vaccines," in Vaccine Design: The Subunit and Adjuvant Approach, Powell, M.F., and Newman, M.J., eds., Plenum Press, New York, NY, pp. 659-671 (1995)				
00000000000000000000000000000000000000	NPL44	Livingston, B.D., et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination are Comparable to Those Elicited by Acute Viral Infection," J. Immunol. 159:1383-1392, The American Association of Immunologists (1997)				
300000000000000000000000000000000000000	NPL45	Manici, S., et al., "Melanoma Cells Present a MAGE-3 Epitope to CD4 ⁺ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11," J. Exp. Med. 189:871-876, The Rockefeller University Press (1999)				
20000000000000000000000000000000000000	NPL46	Morrison, S.L., et al., "Production and Characterization of Genetically Engineered Antibody Molecules," Clin. Chem. 34:1668-1675, Journal of the American Association for Clinical Chemistry, Inc. (1988)				
200000000000000000000000000000000000000	NPL47	Nukaya, I., et al., "Identification of HLA-A24 Epitope Peptides of Carcinoembryonic Antigen Which Induce Tumor-Reactive Cytotoxic Lymphocyte," Int. J. Cancer 80:92-97, Wiley-Liss, Inc. (1999)				
000000000000000000000000000000000000000	NPL48	Pack, P., et al., "Tetravalent Miniantibodies with High Avidity Assembling in Escherichia coli," J. Mol. Biol. 246:28-34, Academic Press Limited (1995)				
V	NPL49	Parham, P., et al., "Carbohydrate Moiety of HLA Antigens," J. Biol. Chem. 252:7555-7567, The American Society of Biological Chemists, Inc. (1977)				
/M.D./	NPL50	Parkhurst, M.R., et al., "Identification of a Shared HLA-A*0201-restricted T-Cell Epitope from the Melanoma Antigen Tyrosinase-related Protein 2 (TRP2)," Cancer Res. 58:4895-4901, The American Association for Cancer Research (1998)				

	Examiner		Date	09/17/2000	
2	000000000000000000000000000000000000000	000000000000000000000000000000000000000	000000000000000000000000000000000000000	4)000000000000000000000000000000000000	2
-	Signature	Marianna DiDrina/	Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	form 1449/PT	0		Со	mplete if Known
				Application Number	10/529,221 (U.S. Nat'l Phase of PCT/US03/30238)
INFORMATION DISCLOSURE				I.A. Filing Date	September 26, 2003
	STATEMENT BY APPLICANT		First Named Inventor	Bruno Robert	
	(Use as many sheets as necessary)			Art Unit	To Be Assigned
			Examiner Name	To Be Assigned	
Sheet	6	of	9	Attorney Docket Number	1843.0200001/EKS/FRC

		NON PATENT LITERATURE DOCUMENTS	
Examine Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
/M.D./	NPL51	Peiper, M., et al., "Pancreatic Cancer Associated Ascites-Derived CTL Recognize a Nine-Amino-Acid Peptide GP2 Derived from HER2/neu," Anticancer Res. 19:2471-2476, International Institute Anticancer Research (1999)	
50000000000000000000000000000000000000	NPL52	Penichet, M.L., et al., "An Antibody-Avidin Fusion Protein Specific for the Transferrin Receptor Serves as a Delivery Vehicle for Effective Brain Targeting: Initial Applications in Anti-HIV Antisense Drug Delivery to the Brain," J. Immunol. 163:4421-4426, The American Association of Immunologists (1999)	
164410000000000000000000000000000000000	NPL53	Ramakrishna, V., et al., "Generation and Phenotypic Characterization of New Human Ovarian Cancer Cell Lines with the Identification of Antigens Potentially Recognizable by HLA-Restricted Cytotoxic T Cells," <i>Int. J. Cancer</i> 73:143-150, Wiley-Liss, Inc. (1997)	
30000000000000000000000000000000000000	NPL54	Ressing, M.E., et al., "Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A*0201-Binding Peptides," J. Immunol. 154:5934-5943, The American Association of Immunologists (1995)	
000000000000000000000000000000000000000	NPL55	Rivoltini, L., et al., "A Superagonist Variant of Peptide MART1/Melan A ₂₇₋₃₅ Elicits Anti-Melanoma CD8 ⁺ T Cells with Enhanced Functional Characteristics: Implication for More Effective Immunotherapy," Cancer Res. 59:301-306, The American Association for Cancer Research (1999)	
000000000000000000000000000000000000000	NPL56	Robert, B., et al., "Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes," Eur. J. Immunol. 30:3165-3170, Wiley-VCH Verlag GmbH (2000)	
000000000000000000000000000000000000000	NPL57	Rongcun, Y., et al., "Identification of New HER2/neu-Derived Peptide Epitopes That Can Elicit Specific CTL Against Autologous and Allogenic Carcinomas and Melanomas," J. Immunol. 163:1037-1044, The American Association of Immunologists (1999)	
\$6000000000000000000000000000000000000	NPL58	Rötzschke, O., et al., "Conformational variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes," Proc. Natl. Acad. Sci. USA 96:7445-7450, National Academy of Sciences (1999)	
V	NPL59	Rötzschke, O., et al., "Superactivation of an immune response triggered by oligomerized T cell epitopes," Proc. Natl. Acad. Sci. USA 94:14642-14647, National Academy of Sciences (1997)	
/M.D./	NPL60	Salazar-Onfray, F., et al., "Synthetic Peptides Derived from the Melanocyte-stimulating Hormone Receptor MC1R Can Stimulate HLA-A2-restricted Cytotoxic T Lymphocytes That Recognize Naturally Processed Peptides on Human Melanoma Cells," Cancer Res. 57:4348-4355, The American Association for Cancer Research (1997)	

Examiner	•	Date	
Signature	/Marianne DiBrino/	Considered	08/17/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for fo	rm 1449/P	го		Con	mplete if Known
				Application Number	10/529,221 (U.S. Nat'l Phase of PCT/US03/30238)
INFORMATION DISCLOSURE				I.A. Filing Date	September 26, 2003
STATEM	ENT B	Y AP	PLICANT	First Named Inventor	Bruno Robert
(U	(Use as many sheets as necessary)			Art Unit	To Be Assigned
	heet 7 of 9		Examiner Name	To Be Assigned	
Sheet			Attorney Docket Number	1843.0200001/EKS/FRC	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
/M.D./	NPL61	Schmitt, L., et al., "Catalysis of peptide dissociation from Class II MHC-peptide complexes," Proc. Natl. Acad. Sci. USA 96:6581-6586, The National Academy of Sciences (1999)	
000000000000000000000000000000000000000	NPL62	Schnell, S., et al., "Retrovirally Transduced Mouse Dendritic Cells Require CD4 ⁺ T Cell Help to Elicit Antitumor Immunity: Implications for the Clinical Use of Dendritic Cells," J. Immunol. 164:1243-1250, The American Association of Immunologists (2000)	
200000000000000000000000000000000000000	NPL63	Shin, SU. and Morrison, S.L., "Production and Properties of Chimeric Antibody Molecules," in <i>Methods in Enzymology, Langone</i> , J.J., ed., Academic Press, Inc., New York, pp. 459-477 (1989)	
	NPL64	Shin, SU., et al., "Functional and Pharmacokinetic Properties of Antibody-Avidin Fusion Proteins," J. Immunol. 158:4797-4804, The American Association of Immunologists (1997)	
	NPL65	Springer, T.A. and Strominger, J.L., "Detergent-soluble HLA antigens contain a hydrophilic region at the COOH-terminus and a penultimate hydrophobic region," <i>Proc. Natl. Acad. Sci. USA 73</i> :2481-2485, The National Academy of Sciences (1976)	
20000000000000000000000000000000000000	NPL66	Steller, M.A., et al., "Cell-mediated Immunological Responses in Cervical and Vaginal Cancer Patients Immunized with a Lipidated Epitope of Human Papillomavirus Type 16 E7," Clin. Cancer Res. 4:2103-2109, The American Association for Cancer Research (1998)	
000000000000000000000000000000000000000	NPL67	Takahashi, T., et al., "707-AP Peptide Recognized by Human Antibody Induces Human Leukocyte Antigen A2-restricted Cytotoxic T Lymphocyte Killing of Melanoma," Clin. Cancer Res. 3:1363-1730, The American Association for Cancer Research (1997)	
	NPL68	Takahashi, T., et al., "Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast Cancer," British J. Cancer 81:342-349, Cancer Research Campaign (1999)	
	NPL69	Tanzarella, S., et al., "Identification of a Promiscuous T-Cell Epitope Encoded by Multiple Members of the MAGE Family," Cancer Res. 59:2668-2674, The American Association for Cancer Research (1999)	
/M.D./	NPL70	Turkewitz, A.P., et al., "Large-Scale Purification of Murine I-A ^k and I-E ^k Antigens and Characterization of the Purified Proteins," Mol. Immunol. 20:1139-1147, Pergamon Press Ltd. (1983)	

- ·		<u> </u>	
Examiner	Marianna DiPrina/	Date	
Signature	/Marianne DiBrino/	Considered	08/17/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0331

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Co	Complete if Known		
				Application Number	10/529,221 (U.S. Nat'l Phase of PCT/US03/30238)		
INFORMATION DISCLOSURE				I.A. Filing Date	September 26, 2003		
STATEM	MENT BY	\mathbf{AP}	PLICANT	First Named Inventor	Bruno Robert		
	(Use as many sheets as necessary)			Art Unit	To Be Assigned		
		Examiner Name	To Be Assigned				
Sheet	8	of	9	Attorney Docket Number	1843.0200001/EKS/FRC		

		Non Patent Literature Documents	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
/M.D./	NPL71	Turner, M.J., et al., "Purification of Papain-solubilized Histocompatibility Antigens from a Cultured Human Lymphoblastoid Line, RPMI 4265*," J. Biol. Chem. 250:4512-4519, The American Society of Biological Chemists, Inc. (1975)	
75555555555555555555555555555555555555	NPL72	Valmori, D., et al., "Analysis of MAGE-3-specific Cytolytic T Lymphocytes in Human Leukocyte Antigen-A2 Melanoma Patients," Cancer Res. 57:735-741, The American Association for Cancer Research (1997)	
00000000000000000000000000000000000000	NPL73	Valmori, D., et al., "Analysis of the Cytolytic T Lymphocyte Response of Melanoma Patients to the Naturally HLA-A*0201-associated Tyrosinase Peptide 368-376," Cancer Res. 59:4050-4055, The American Association for Cancer Research (1999)	
NPL74 Restricted CTL Specific for the Immunodominant Melan-A/MART-1 Antigenic I		Valmori, D., et al., "Diversity of the Fine Specificity Displayed by HLA-A*0201-Restricted CTL Specific for the Immunodominant Melan-A/MART-1 Antigenic Peptide," J. Immunol. 161:6956-6962, The American Association of Immunologists (1998)	
BEAUTO-000000000000000000000000000000000000	NPL75	Wang, RF., et al., "Recognition of an Antigenic Peptide Derived from Tyrosinase-Related Protein-2 by CTL in the Context of HLA-A31 and -A33," J. Immunol. 160:890-897, The American Association of Immunologists (1998)	
***************************************	NPL76	Wizel, B., et al., "HLA-A2-Restricted Cytotoxic T Lymphocyte Responses to Multiple Plasmodium falciparum Sporozoite Surface Protein 2 Epitopes in Sporozoite-Immunized Volunteers," J. Immunol. 155:766-775, The American Association of Immunologists (1995)	
***************************************	NPL77	Wizel, B., et al., "Human Infection with Trypanosoma cruzi Induces Parasite Antigen- Specific Cytotocxic T Lymphocyte Responses," J. Clin. Invest. 102:1062-1071, The American Society for Clinical Investigation, Inc. (1998)	
3000-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7	Zarour, H.M., et al., "Melan-A/MART-1 _{51.73} represents an immunogenic HLA-DR4- restricted epitope recognized by melanoma-reactive CD4 ⁺ T Cells," <i>Proc. Natl. Acad. Sci. USA 97</i> :400-405, The National Academy of Sciences (2000)		
NPL79 Zarutskie, J.A., et al., "A Conformational Change in the Human Major Histocompatibility Complex Protein HLA-DR1 Induced by Peptide Binding," Biochemistry 38:5878-5887, American Chemical Society (1999)			
/M.D./	NPL80	Zhang, Hf., et al., "Targeting of functional antibody-CD59 fusion proteins to a cell surface," J. Clin. Invest. 103:55-61, The American Society for Clinical Investigation (1999)	

Examiner Signature	/Marianne DiBrino/	Date Considered	08/17/2009
Digitature	mananio Bibinio,	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Col	mplete if Known		
				Application Number	10/529,221 (U.S. Nat'l Phase of PCT/US03/30238)
INFORMATION DISCLOSURE				I.A. Filing Date	September 26, 2003
			PLICANT	First Named Inventor	Bruno Robert
((Use as many	sheets a	s necessary)	Art Unit	To Be Assigned
		Examiner Name	To Be Assigned		
Sheet	9	of	9	Attorney Docket Number	1843.0200001/EKS/FRC

		Non Patent Literature Documents	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
/M.D./	NPL81	Zhu, X., et al., "A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of α chain, β chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens," Eur. J. Immunol 27:1933-1941, Verlagsgesellschaft (1997)	

447473 1.DOC

Examiner	/Marianne DiBrino/	Date Considered	08/17/2009
Signature		Considered	00/17/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



In re application of:

ROBERT et al.

Appl. No.: 10/529,221 (U.S. Nat'l Phase

of PCT/US03/30238)

I.A. Filed: September 26, 2003

For: Targeted CD1d Molecules

Confirmation No.: 2116
Art Unit: To Be Assigned

Examiner: To Be Assigned

Atty. Docket: 1843.0200001/EKS/FRC

First Supplemental Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO/SB/08A and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents **FP12-FP15** and **NPL82-NPL91** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and U.S. patent application publications, documents **US4-US13**, cited on the attached Form PTO/SB/08A are not submitted.

The Examiner's attention is directed to the following co-pending U.S. Patent Applications, which are directed to related technical subject matter:

Application No. 10/809,790, inventors Zauderer, M., et al., filed March 26, 2004, now published as 2004/0210037 A1, cited herein as document **US12**: and

Application No. 10/887,230, inventor Zauderer, M., filed July 9, 2004, now published as 2005/0042218 A1, cited herein as document US13.

The identification of these U.S. Patent Applications is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Frank R. Cottingham Attorney for Applicants

Registration No. 50,437

Date: <u>AUG. 15</u> 2006

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

458653_1.DOC

Equivalent of Form PTO/SB/08A (07-05) Approved for use through 07/31/2006. U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 sons are required to respond to a collection of information unless it contains a valid OMB control number. TRADENARY

Substitute for form 1449/PTO

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet of 1

Complete if Known				
Application Number	10/529,221 (U.S. Nat'l Phase of PCT/US03/30238)			
I.A. Filing Date	September 26, 2003			
First Named Inventor	Bruno Robert			
Art Unit	To Be Assigned			
Examiner Name	To Be Assigned			
Attorney Docket Number	1843.0200001/EKS/FRC			

			U.S. PATENT DO	OCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,
Initials*	itials* No.1 Number-Kind Code ^{2 (If Known)} MM		MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear
/M.D./	US4	6,248,564 B1	06/19/2001	Walter et al.	
8	US5	6,548,067 B1	04/15/2003	Seeman et al.	
20000	US6	6,682,741 B1	01/27/2004	Ribaudo et al.	
000000	US7	6,881,828 B2	04/19/2005	Edwards et al.	
900000	US8	2002/0051783 A1	05/02/2002	Savage	
	US9	2002/0071842 A1	06/13/2002	Gumperz et al.	
0000	US10	2002/0155447 A1	10/24/2002	Zauderer et al.	
	US11	2003/0166277 A1	09/04/2003	Zauderer and Smith	
W	US12	2004/0210037 A1	10/21/2004	Zauderer et al.	
/M.D./	US13	2005/0042218 A1	02/24/2005	Zauderer	
_					

			FOREIGN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			Relevant Passages or Relevant Figures Appear	T ⁶
/M.D./	FP12	WO 94/25610 A1	11/10/1994	Tykocinski		
/M.D./	FP13	WO 99/64597 A1	12/16/1999	The Government of the United States of America represented by The Secretary, Department of Health and Human Services		
/M.C	, <i> </i> FP14	GB 2 339 782 A	02/09/2000	Savage		
/M.D.	FP15	WO 04/029206 A2	04/08/2004	Vaccinex, Inc. and Robert et al.		

453216 1.DOC

Examiner Signature /Marianne DiBrino/	Date Considered	08/17/2009
---------------------------------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no personnel requires point to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
FIRST SU	PPLEM	IENT	ΓΑL	Application Number	10/529,221 (U.S. Nat'l Phase of PCT/US03/30238)	
INFORMA	ATION	DISC	CLOSURE	I.A. Filing Date	September 26, 2003	
				First Named Inventor	Bruno Robert	
	STATEMENT BY APPLICANT (Use as many sheets as necessary)			Art Unit	To Be Assigned	
			· · · · · · · · · · · · · · · · · · ·	Examiner Name	To Be Assigned	
Sheet	1	of	1	Attorney Docket Number 1843.0200001/EKS/FRC		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
/M.D./	NPL82	Fayen, J., et al., "Class I MHC Alpha 3 Domain Can Function as an Independent Structural Unit to Bind CD8α," Mol. Immunol. 32:267-275, Elsevier Science Ltd. (1995)	
221000000000000000000000000000000000000	NPL83	Glick, M., et al., "Novel CD8 ⁺ T Cell Antagonists Based on β ₂ -Microglobulin," J. Biol. Chem. 277:20840-20846, The American Society for Biochemistry and Molecular Biology, Inc. (June 2002)	
***************************************	NPL84	Hebert, A.M., et al., "Kinetics and Thermodynamics of β2-Microglobulin Binding to the α3 Domain of Major Histocompatibility Complex Class I Heavy Chain," Biochem. 40:5233-5242, American Chemical Society (published online March 2001)	
000000000000000000000000000000000000000	NPL85	Hochman, J.H., et al., "Specific Associations of Fluorescent β -2-Microglobulin with Cell Surfaces. The Affinity of Different H-2 and HLA Antigens for β -2-Microglobulin," J. Immunol. 140:2322-2329, The American Association of Immunologists (1988)	
	NPL86	Mottez, E., et al., "Cells Expressing a Major Histocompatibility Complex Class I Molecule with a Single Covalently Bound Peptide Are Highly Immunogenic," J. Exp. Med. 181:493-502, Rockefeller University Press (1995)	
	NPL87	Parker, K.C., and Strominger, J.L., "Subunit Interactions of Class I Histocompatibility Antigens," <i>Biochem.</i> 24:5543-5550, American Chemical Society (1985)	
000000000000000000000000000000000000000	NPL88	Salter, R.D., et al., "A binding site for the T-cell co-receptor CD8 on the α ₃ domain of HLA-A2," Nature 345:41-46, Nature Publishing Group (1990)	
200000000000000000000000000000000000000	NPL89	Sidney, J., et al., "Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs," <i>Immunol. Today 17</i> :261-266, Elsevier Science Ltd. (1996)	
V	NPL90	Sidney, J., et al., "Majority of Peptides Binding HLA-A*0201 With High Affinity Crossreact With Other A2-Supertype Molecules," Hum. Immunol. 62:1200-1216, Elsevier Science Inc. (November 2001)	
/M.D./	NPL91	Whitman, M.C., et al., "The isolated major histocompatibility complex class I α3 domain binds β2m and CD8αα dimers," Mol. Immunol. 37:141-149, Elsevier Science Ltd. (2000)	

453214_1.DOC

Examiner		Date	0014710000
Signature	/Marianne DiBrino/	Considered	08/17/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.